Celerion gets USP 797 OK for Ph I cleanroom

By Gareth Macdonald

- Last updated on GMT

Related tags Clinical trial Pharmacology

US CRO Celerion is to expand in-house compounding for microtracer studies after gaining certification for cleanroom and pharmacists at its Ph I unit in Lincoln, Nebraska.

The certification, covered by United States Pharmacopoeia (USP) guideline 797 on sterile preparations, allows the firm to offer compounding for medium and high risk candidates, whereas previously it was only able to handle low risk compounds.

Celerion spokeswoman Farzana Azam told Outsourcing-pharma.com that this in-house capability “Is a unique service in North America that is not offered by our peers which will save clients both time and money.

Previously our Sponsors needed to arrange for external manufacturing and sterilization to facilitate delivery of the sterile drug to the clinic where we would conduct the clinical protocol accordingly under a separate contract.

She explained that, in practice, this meant having to manage multiple contracts and obtain certificates of analysis (CoA) from several vendors, costing the sponsor additional time and money.

Today our sponsors would be able to hold one contract with Celerion. They would be able to ship their API and we would be able to prepare the drug on site and transfer the sterile solution to the clinical floor for administration according the protocol​.”

Celerion employs two full time pharmacists at the Lincoln facility, both of whom also received training in USP <797> requirements for compounding procedures and sterilisation methods from BAXA and PCCA.

The microdosing expansion is one of a number of additions early-phase trials specialist Celerion has made to its business since its launch following the break up of MDS Pharma Services in 2010.

In June​ the firm added hybrid ECG core laboratory capabilities to streamline the process of heart monitoring in early phase clinical trials.

More recently​ it partnered with BryanLGH Health System to add extra capacity for first in human trials at the Lincoln site, citing growing industry and regulatory demand for “in hospital” Phase I studies.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more